Analysis of Multiple Sarcoma Expression Datasets: Implications for Classification, Oncogenic Pathway Activation and Chemotherapy Resistance

Panagiotis A. Konstantinopoulos(Harvard University), Dimitrios Spentzos(Beth Israel Deaconess Medical Center), Nancy Francoeur(Icahn School of Medicine at Mount Sinai), Jeffrey D. Goldsmith(Beth Israel Deaconess Medical Center), Mark C. Gebhardt(Massachusetts General Hospital), Towia A. Libermann(Beth Israel Deaconess Medical Center), Manoj Bhasin(Emory University), Elena Fountzilas(European University Cyprus), Kamana Pillay(Beth Israel Deaconess Medical Center)
PLoS ONE
April 1, 2010
10.1371/journal.pone.0009747
Cited by 24

Related Papers

Review of precision cancer medicine: Evolution of the treatment paradigm
|Cancer Treatment Reviews|2020|747
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
|European Journal of Cancer|2019|724
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
|Oncotarget|2016|616
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
|The Lancet Oncology|2016|537
Gene Expression Profile of <i>BRCA</i>ness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
|Journal of Clinical Oncology|2010|488